Syndax Pharmaceuticals
Update in progressSNDX (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Syndax Pharmaceuticals is a commercial-stage biopharma company focused on cancer therapies. Its lead candidates include Revuforj (revumenib), a menin inhibitor for relapsed or refractory acute leukemias, and Niktimvo (axatilimab-csfr), an anti-CSF-1R antibody for chronic graft-versus-host disease. The firm also pursues revumenib for mNPM1 AML and other leukemias, metastatic colorectal cancer, axatilimab for idiopathic pulmonary fibrosis, and Entinostat, a Class I HDAC inhibitor, under license from Eddingpharm. Based in New York since 2005.
Company score
- Sentiment
- 0.18
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.23
- Governance
- 0.08
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.09
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.13
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEOMr. Michael A. Metzger M.B.A.
- Founded2005
- Employees298
- Websitesyndax.com
Identifiers
- ISINUS87164F1057
- FIGIBBG000R33JY1
- LEI529900OF94TRHKZVBS87
- CUSIP87164F105
- CIK0001395937